Abstract

A Recommendation to Enhance the Outcomes of

Author(s): Kan Gong

Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled growth of plasma cells in the bone marrow, leading to significant morbidity and mortality. Although various treatment options, including chemotherapy and autologous stem cell transplantation, have been utilized, relapsed or refractory multiple myeloma (r/r MM) remains a critical challenge. Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a promising treatment for r/r MM, especially in patients who have failed previous therapies. Recent studies have focused on enhancing platelet function through CAR-T cell therapy to improve clinical outcomes. This article offers a perspective on strategies to optimize the effectiveness of CAR-T therapy by enhancing platelet function, thereby improving treatment outcomes in relapsed/refractory multiple myeloma.